logo
logo
Avanos Medical, Inc.

Avanos Medical, Inc.

NYSE•AVNS
CEO: Mr. Michael C. Greiner CPA
セクター: Healthcare
業種: Medical - Devices
上場日: 2014-10-21
Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
連絡先情報
5405 Windward Parkway, Suite 100 South, Alpharetta, GA, 30004, United States
844-428-2667
avanos.com
時価総額
$683.29M
PER (TTM)
-1.5
38.4
配当利回り
--
52週高値
$16.78
52週安値
$9.30
52週レンジ
72%
順位60Top 89.2%
2.1
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.1 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$177.80M+4.34%
直近4四半期の推移

EPS

-$0.03-132.30%
直近4四半期の推移

フリーCF

$7.00M-65.00%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Total Net Sales Increased Total Net Sales reached $520.3 M for nine months, reflecting a 2.4% increase over prior period results.
Specialty Nutrition Sales Growth SNS segment sales were $317.8 M for nine months, driven by 9.1% volume growth across product lines.
Operating Cash Flow Improved Cash provided by operating activities totaled $46.5 M for nine months, slightly up from $42.8 M last year.
Completed Nexus Medical Acquisition Acquired Nexus Medical for $27.0 M cash plus contingent consideration, enhancing Specialty Nutrition Systems portfolio.

リスク要因

Significant Goodwill Impairment Recorded $77.0 M goodwill impairment charge in Q2 2025 after market cap decline indicated fair value below carrying amount.
Nine Month Net Loss Reported Net Loss of $(71.6) M for nine months ended September 30, 2025, compared to $5.2 M income prior year.
Tariff and Trade Restriction Risks New and increased US tariffs pose material adverse effect risk due to reliance on Mexican manufacturing and global sourcing.
Healthcare Reimbursement Uncertainty Failure of healthcare programs to maintain coverage or reductions in reimbursement could negatively impact product demand and pricing.

見通し

Restructuring Plan Expansion Plan expanded post-Q3 2025, expecting up to $10.0 M incremental severance costs running through the end of 2026.
Anticipated Restructuring Savings Anticipate annualized savings between $15.0 M and $20.0 M resulting from organizational structure alignment initiatives.
Nexus Valuation Finalization Expected Expect final purchase price allocation valuations for Nexus acquisition to be substantially complete by the end of 2025.
Sufficient Liquidity Expected Expect operating cash flow and borrowing capacity sufficient to fund working capital and capital expenditures next twelve months.

同業比較

売上高 (TTM)

Community Health Systems, Inc.CYH
$12.64B
+0.7%
Varex Imaging CorporationVREX
$854.40M
+4.1%
Orthofix Medical Inc.OFIX
$818.06M
+4.3%

粗利益率 (最新四半期)

Bicycle Therapeutics plcBCYC
100.0%
+1705.8pp
OrthoPediatrics Corp.KIDS
73.9%
+0.5pp
Orthofix Medical Inc.OFIX
72.2%
+3.5pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
BFLY$861.37M-10.8-37.8%7.3%
AVNS$683.29M-1.5-58.2%12.5%
VREX$593.16M-8.4-13.9%36.3%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-0.3%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年2月25日
|
EPS:$0.24
|
売上高:$174.70M
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月5日|
    売上高: $177.80M+4.3%
    |
    EPS: $-0.03-132.3%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月5日|
    売上高: $175.00M+1.9%
    |
    EPS: $-1.66-4334.7%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月6日|
    売上高: $167.50M+0.8%
    |
    EPS: $0.14-817.9%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月26日|
    売上高: $687.80M+2.2%
    |
    EPS: $-8.53-541.4%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年10月30日|
    売上高: $170.40M-0.5%
    |
    EPS: $0.09-218.2%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年7月31日|
    売上高: $171.70M+1.4%
    |
    EPS: $0.04-102.7%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月2日|
    売上高: $166.10M+4.3%
    |
    EPS: $-0.02+82.2%
    予想を下回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月21日|
    売上高: $673.30M-1.6%
    |
    EPS: $-1.33-223.1%
    予想を下回る